[高效抗逆转录病毒疗法对艾滋病相关卡波西肉瘤演变的影响]

[Influence of highly active antiretroviral therapy on the evolution of AIDS-associated Kaposi's sarcoma].

作者信息

Bulla F, Conill C, Mallolas J, Lecha M

机构信息

Dermatología. Hospital Clínic. Barcelona.

出版信息

Med Clin (Barc). 2000 Dec 2;115(19):736-7. doi: 10.1016/s0025-7753(00)71677-0.

DOI:10.1016/s0025-7753(00)71677-0

PMID:11141440

Abstract

BACKGROUND

To evaluate the highly active antiretroviral therapy (HAART) in the Kaposi's sarcoma evolution.

PATIENTS AND METHOD

Retrospective analysis of a cohort of 126 HIV infected patients suffering from Kaposi's sarcoma with or without HAART. Clinical evolution, immunological status (CD4+ cell count) and response to therapy (HIV-RNA plasma viral load and human herpes-8 virus determination).

RESULTS

All patients without HAART died and the cumulate probability survival (SD) among those who received HAART was 2.078 (74) days. The CD4+ count at baseline in the HAART group was 130 (125) * 106/l and the HIV-RNA viral load was 196,818 (244,195) copies/ml while at the moment of the clinical response was 235 (209) * 106/l CD4 + and 2,629 (6.444) copies/ml, respectively.

CONCLUSION

HAART prolongs survival in HIV patients suffering from Kaposi's sarcoma. There is a clear relationship among clinical response, HAART and immunological recovery.

摘要

背景

评估高效抗逆转录病毒疗法（HAART）对卡波西肉瘤病程的影响。

患者与方法

对126例感染人类免疫缺陷病毒（HIV）且患有卡波西肉瘤的患者进行回顾性分析，这些患者接受或未接受HAART治疗。观察临床病程、免疫状态（CD4 +细胞计数）以及治疗反应（HIV-RNA血浆病毒载量和人类疱疹病毒8型检测）。

结果

所有未接受HAART治疗的患者均死亡，接受HAART治疗患者的累积生存概率（标准差）为2.078（74）天。HAART组基线时CD4 +细胞计数为130（125）×10⁶ /L，HIV-RNA病毒载量为196,818（244,195）拷贝/毫升，而出现临床反应时CD4 +细胞计数分别为235（209）×10⁶ /L，HIV-RNA病毒载量为2,629（6,444）拷贝/毫升。